"Razoxane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimitotic agent with immunosuppressive properties.
| Descriptor ID |
D011929
|
| MeSH Number(s) |
D03.383.606.385.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Razoxane".
Below are MeSH descriptors whose meaning is more specific than "Razoxane".
This graph shows the total number of publications written about "Razoxane" by people in this website by year, and whether "Razoxane" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Razoxane" by people in Profiles.
-
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
-
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29; 109(25):3122-31.
-
Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996 Feb; 14(2):362-72.
-
Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982 Jun; 127(6):1238-42.
-
Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1982 Apr; 42(4):1390-4.
-
Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett. 1981 Jul; 13(2):139-45.
-
Effect of surgery and adjuvant chemotherapy on the R3327 MAT-Ly Lu tumor. Prostate. 1981; 2(3):299-307.
-
Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates. Cancer Treat Rep. 1980 Apr-May; 64(4-5):734-6.